Month: May 2023

Increased hashrate capacity by 65% in Q1 2023 to 3.3 EH/s as of March 31, 2023. Self-mined 533 Bitcoin in Q1 2023, an increase of 38% over the Bitcoin self-mined in Q4 2022. Revenue per Bitcoin produced increased 28% in Q1 2023, while power cost per Bitcoin declined by 21%. EASTON, Md., May 15, 2023 (GLOBE NEWSWIRE) — TeraWulf Inc. (Nasdaq: WULF) (“TeraWulf” or the “Company”), which owns and operates vertically integrated, domestic Bitcoin mining facilities powered by more than 91% zero-carbon energy, today announced its unaudited financial results for the first quarter of fiscal year 2023 and provided an operational update. First Quarter 2023 Operational and Financial Highlights        Generated revenue of $12.3 million and self-mined 533 Bitcoin in Q1 2023. Commenced mining at the Nautilus Cryptomine in February 2023, a joint...

Naples, FL, May 15, 2023 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC:SONG) today announced its financial results for the first quarter ended March 31, 2023. The company’s financial results are reported in USD. Financial HighlightsTotal Revenues for Q1 2023 were $14,978,841, driven by our core services. This represents robust revenue growth and highlights the strength and scalability of our business model. Net Income for the quarter was $14,958,174, reflecting the operational efficiency of our business and our continued focus on profitability. Total Assets as of March 31, 2023, stood at $14,992,755. Total Liabilities were significantly low, amounting to $104,286, demonstrating the company’s strong financial health. Total Equity increased to $14,888,469 as of March 31, 2023, primarily due to retained earnings of $14,659,102.Key...

NORCROSS, Ga., May 15, 2023 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2023. These results are included in the Company’s Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said: “Our entire team is actively engaged in oversight and management of our adaptively designed Phase 2b/3 NAVIGATE trial for the prevention of esophageal varices in patients with NASH cirrhosis, which completed randomization of 357 patients in February 2023. Our stated target remains obtaining interim analysis...

– Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as an oral presentation at ASCO 2023 – – As presented at AACR 2023, STRO-003 demonstrated potent anti-tumor activity and immune-modulating properties in preclinical models, suggesting its potential to augment checkpoint blockade therapy – – As of March 31, 2023, Sutro had cash and investments of $251.5 million and shares of Vaxcyte common stock valued at $25.0 million, which together provide a projected cash runway into the second half of 2024 – SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug...

YONKERS, N.Y., May 15, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces business updates and financial results for the first quarter ended March 31, 2023. “As a physician-scientist, I am truly excited to have begun dosing patients in our Phase 1b/2 clinical study of intra-articular exebacase for the treatment of chronic prosthetic joint infections of the knee. There has been no change in the standard of care for this disease, which is surgical revision, in the past 40-plus years and we finally have the potential to change the paradigm,” said Roger J. Pomerantz,...

Announces Q1 2023 Revenue of $9.9 million Announces record Q1 Gross Profit of $5.1 million (51.2%) Announces record Q1 Adjusted EBITDA of $1.0 million (9.6%) Reaffirms 2023 Revenue Guidance of $60 million Projects Backlog Revenue of up to $110 millionLOUISVILLE, Ky., May 15, 2023 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX, CREXW), a leading provider of digital signage and media solutions, announced its financial results for the first quarter ended March 31, 2023. Rick Mills, Chief Executive Officer, commented “I am pleased to report that the Company generated first quarter 2023 revenue of $9.9 million with first quarter records of $5.1 million and approximately $960 thousand in gross profit and Adjusted EBITDA, respectively. This translates to first quarter gross...

9 subjects enrolled into the OPMD clinical development program HAYWARD, Calif., May 15, 2023 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its Third Fiscal Quarter ended March 31, 2023. The Company has filed its quarterly report on Form 10-Q for the quarter ended March 31, 2023 with the U.S. Securities and Exchange Commission. “We continue to screen and enroll OPMD subjects into the Natural History Study at the U.S. clinical study site, and enrollment is proceeding at a rapid pace,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec....

Revenue of $5.3 million in Q1 compared to $6.2 million a year ago when Company recognized $850,000 in software revenue for one-time consulting project; Q1 2023 revenue also impacted by lower cattle headcounts, inflation-based shift in consumer food preferences and severe weather that delayed verification activity and tag sales Net income of $0.1 million vs. $0.5 million a year ago, reflecting lower gross margins and increased SG&A related to post-Covid re-start of industry trade shows, on-site audit staff training and Nasdaq listing eventAdjusted EBITDA of $0.4 million vs. $0.9 million last year reflects lower net income, income tax expense, depreciation and amortization and stock-based compensation charges Company continues share repurchase program, buying back $1.2 million of stock (89,450 shares) in the first quarterCASTLE ROCK,...

TORONTO, May 15, 2023 (GLOBE NEWSWIRE) — Unisync Corp. (“Unisync”) (TSX:”UNI”) (OTCQX:”USYNF”) announces its audited financial results for the second quarter ended March 31, 2023 of its 2023 fiscal year (“Q2 2023”). Unisync operates through two business units: Unisync Group Limited (“UGL”) with operations throughout Canada and the USA and 90% owned Peerless Garments LP (“Peerless”), a domestic manufacturing operation based in Winnipeg, Manitoba. UGL is a leading customer-focused provider of corporate apparel, serving many leading Canadian and American iconic brands. Peerless specializes in the production and distribution of highly technical protective garments, including military operational clothing and accessories for a broad spectrum of Federal, Provincial and Municipal government departments...

End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy (DR) PDUFA date for Nyxol First Indication in Reversal of Pharmacologically-Induced Mydriasis (RM) Set for September 28, 2023; Nyxol Development and Commercialization Funded by Viatris Cash Balance of $39 Million Expected to Fund Operations into 2025 FARMINGTON HILLS, Mich., May 15, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update. “Ocuphire made significant progress across both our APX3330 and Nyxol programs...